Hypoglycemia, or low blood sugar, occurs when glucose levels fall below 70 mg/dL, critically affecting brain function and ...

"FDA's granting of Orphan Drug Designation is a recognition of the serious unmet need patients with tumor hyperinsulinism face and validates the potential significant benefit that ersodetug can ...

A new study by the University of California, Davis, shows how cells work together to avoid a sudden drop in blood sugar. Understanding these feedback loops could improve the lives of people with ...

Hypoglycemia is the term for low levels of sugar in the blood. Refractory hypoglycemia occurs when hypoglycemia lasts for a prolonged period of time, such as a few hours to a few days. Refractory ...

REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by HI, ...

Risk factors for hypoglycemia include mismatch of insulin timing, amount or type of carbohydrate intake, taking oral secretagogues without adequate carbohydrate intake, history of severe hypoglycemia, ...

Hypoglycemia occurs when blood sugar (glucose) levels fall below 70 milligrams per deciliter, creating a medical emergency that requires immediate treatment. The condition affects people with and ...

Hypoglycemia is when blood sugar levels fall below a range normal for that individual. Common symptoms of hypoglycemia in children include shakiness, sweating, and irritability. Hypoglycemia is also ...

Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism (HI) Ersodetug continues to advance in ...

Phase 3 registrational trial for ersodetug in patients with tumor hyperinsulinism (HI) expected to commence in 2025; real-world patient benefit demonstrated in Expanded Access Program REDWOOD CITY, ...